创新药板块持续走低，恒生医疗ETF(513060)跌超2%，成交额超10亿元
Xin Lang Cai Jing·2025-05-12 05:49

Group 1 - The Hang Seng Healthcare Index (HSHCI) has decreased by 3.31% as of May 12, 2025, with mixed performance among constituent stocks [3] - Leading gainers include Yuan Da Pharmaceutical (00512) up 15.80%, Alibaba Health (00241) up 3.82%, and Haijia Medical (06078) up 3.73% [3] - Major decliners include BeiGene (06160) down 9.47%, Ascentage Pharma-B (06855) down 8.21%, and 3SBio (01530) down 8.11% [3] Group 2 - The Hang Seng Healthcare ETF (513060) has decreased by 2.51%, with a latest price of 0.47 yuan and a turnover rate of 10.59% [3] - The ETF's trading volume reached 1.03 billion yuan, indicating active market participation [3] - As of May 9, 2025, the ETF's average daily trading volume over the past month was 1.516 billion yuan, ranking first among comparable funds [3] Group 3 - According to Kaiyuan Securities, the industry adjustment is nearing its end, and the pharmaceutical index is stabilizing [3] - The pharmaceutical index has been under pressure since 2021 but began to stabilize from Q4 2024 [3] - Long-term trends such as unmet clinical needs due to aging and increasing innovation capabilities remain unchanged, suggesting potential for stable growth in the pharmaceutical sector [3] Group 4 - The Hang Seng Healthcare ETF has a current size of 9.996 billion yuan, ranking in the top third among comparable funds [4] - The ETF's financing buy-in amount is 107 million yuan, with a financing balance of 387 million yuan [4] - The ETF has achieved a 24.20% net value increase over the past year, with a maximum monthly return of 28.34% since inception [4] Group 5 - The ETF's management fee is 0.50%, and the custody fee is 0.15% [5] - The tracking error for the ETF over the past month is 0.030%, indicating the highest tracking precision among comparable funds [5] - The latest price-to-earnings ratio (PE-TTM) for the HSHCI is 23.74, which is below 96% of the historical data over the past year, indicating a low valuation [5] Group 6 - The top ten weighted stocks in the HSHCI account for 56.73% of the index, with WuXi Biologics (02269) and BeiGene (06160) being the largest components [5]